D&A at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's D&A?
- Pacific Biosciences of California (PACB) reported D&A of $2.2M in Q1 2026.
- How has Pacific Biosciences of California's D&A changed year-over-year?
- Pacific Biosciences of California's D&A decreased by 57.1% year-over-year, from $5.13M to $2.2M.
- What is the long-term trend for Pacific Biosciences of California's D&A?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's D&A has grown at a 15.9% compound annual growth rate (CAGR), from $7.2M to $12.99M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.